Management of heart failure in primary care and the use of Forxiga (dapagliflozin)
AstraZeneca have provided financial support for this blended learning series and have had no involvement in the content or speaker selection
The Primary Care Cardiovascular Society (PCCS) presents its first blended learning series of educational resources.
This series covers the NICE technology appraisal guidance for dapagliflozin for the symptomatic treatment of heart failure with reduced ejection fraction (HFrEF), providing an update on its new licenced indication and focusing on the recommendations for its use within clinical practice in primary care.
The series consists of three assets:
The blended learning series is accredited by the PCCS for CPD points.